Investors with a lot of money to spend have taken a bullish stance on Insmed INSM.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INSM, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 9 uncommon options trades for Insmed.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $56,594, and 7 are calls, for a total amount of $570,700.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Insmed over the recent three months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Insmed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Insmed's significant trades, within a strike price range of $25.0 to $70.0, over the past month.
Insmed Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM | CALL | TRADE | NEUTRAL | 06/21/24 | $40.6 | $38.4 | $39.35 | $25.00 | $157.4K | 9.7K | 0 |
| INSM | CALL | TRADE | BULLISH | 06/21/24 | $37.2 | $35.8 | $37.2 | $27.50 | $148.8K | 358 | 0 |
| INSM | CALL | TRADE | BEARISH | 06/21/24 | $24.9 | $23.9 | $24.23 | $40.00 | $121.1K | 7.6K | 28 |
| INSM | CALL | TRADE | BEARISH | 06/21/24 | $25.5 | $25.0 | $25.0 | $40.00 | $50.0K | 7.6K | 4 |
| INSM | CALL | TRADE | BULLISH | 07/19/24 | $20.6 | $20.1 | $20.45 | $45.00 | $40.9K | 24.3K | 0 |
About Insmed
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Following our analysis of the options activities associated with Insmed, we pivot to a closer look at the company's own performance.
Where Is Insmed Standing Right Now?
- With a volume of 1,095,506, the price of INSM is down -2.04% at $64.24.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 42 days.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Insmed, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
